- Home
- MNTK vs MLYS Comparison
MNTK vs MLYS Comparison
Compare MNTK & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNTK
- MLYS
- Stock Information
- Founded
- MNTK 1980
- MLYS 2019
- Country
- MNTK United States
- MLYS United States
- Employees
- MNTK 166
- MLYS N/A
- Industry
- MNTK Natural Gas Distribution
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- MNTK Utilities
- MLYS Health Care
- Exchange
- MNTK Nasdaq
- MLYS Nasdaq
- Market Cap
- MNTK 339.0M
- MLYS 1.0B
- IPO Year
- MNTK 2021
- MLYS 2023
- Fundamental
- Price
- MNTK $2.25
- MLYS $14.31
- Analyst Decision
- MNTK Hold
- MLYS Strong Buy
- Analyst Count
- MNTK 3
- MLYS 4
- Target Price
- MNTK $3.33
- MLYS $27.00
- AVG Volume (30 Days)
- MNTK 228.9K
- MLYS 887.7K
- Earning Date
- MNTK 08-07-2025
- MLYS 08-12-2025
- Dividend Yield
- MNTK N/A
- MLYS N/A
- EPS Growth
- MNTK N/A
- MLYS N/A
- EPS
- MNTK 0.05
- MLYS N/A
- Revenue
- MNTK $179,552,000.00
- MLYS N/A
- Revenue This Year
- MNTK $3.00
- MLYS N/A
- Revenue Next Year
- MNTK $13.24
- MLYS N/A
- P/E Ratio
- MNTK $43.78
- MLYS N/A
- Revenue Growth
- MNTK N/A
- MLYS N/A
- 52 Week Low
- MNTK $1.68
- MLYS $8.24
- 52 Week High
- MNTK $6.13
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- MNTK 50.94
- MLYS 49.37
- Support Level
- MNTK $2.20
- MLYS $13.44
- Resistance Level
- MNTK $2.78
- MLYS $14.70
- Average True Range (ATR)
- MNTK 0.19
- MLYS 0.68
- MACD
- MNTK 0.00
- MLYS 0.04
- Stochastic Oscillator
- MNTK 41.63
- MLYS 77.43
About MNTK Montauk Renewables Inc.
Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.